Are GLP-1 Drugs Quietly Changing Our Sex Lives?
Friday, April 10, 2026 – Saturday, April 11 - Here’s everything we know so far.
Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera option
Friday, April 10, 2026 – Saturday, April 11 - New China-US biotech gets $54M: Vivatides Therapeutics raised the Series A for its preclinical-stage R&D in siRNA and antisense oligonucleotides aimed at reaching tissues beyond the liver. Vivatides’ investors include ...
AI scans 400,000 Reddit posts to flag overlooked GLP-1 side effects
Friday, April 10, 2026 – Friday, April 10 - By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.
Novo’s double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim
Friday, April 10, 2026 – Friday, April 10 - → A decorated GLP-1 pioneer is retiring at Novo Nordisk.
Channeling Elvis Presley with a microphone emoji for good measure, Lotte Bjerre Knudsen said on LinkedIn that she “has left the ...
Divorce boom may follow use of Ozempic and other GLP-1 drugs, experts warn
Friday, April 10, 2026 – Friday, April 10 - Research suggests GLP-1 drugs like Ozempic and Wegovy could double divorce risk, mirroring trends seen in bariatric surgery patients, experts say.
AI-based monitoring reveals protein deficiencies in people taking GLP-1 receptor agonists for weight loss
Thursday, April 9, 2026 – Friday, April 10 - Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat significantly less, leaving them vulnerable to nutritional deficiencies, according to one of the first real-world studies to examine dietary behavior in people using glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists RAs (collectively referred to as GLP-1 RAs) with the help of an AI-powered nutritional tracking app.
Call to Integrate Obesity Management With Surgery, GLP-1s Into Cancer Care
Thursday, April 9, 2026 – Friday, April 10 - (MedPage Today) -- Integrating the most effective obesity treatments into cancer survivorship offers "an unprecedented opportunity" to improve long-term outcomes in cancer, including survival, a trio of obesity and oncology specialists argued in...
STAT+: Genetics may shape GLP-1 outcomes, slightly
Thursday, April 9, 2026 – Friday, April 10 - The traditional biotech venture model under pressure, PhRMA chief Ubl to exit, and other biotech news from The Readout
STAT+: Pharmalittle: We’re reading about top pharma lobbyist stepping down, genes and GLP-1 drugs, and more
Thursday, April 9, 2026 – Friday, April 10 - Steve Ubl, chief executive of PhRMA, plans to step down at the end of the year, after more than a decade leading the main trade group for brand-name drug makers
Genetic predictors for GLP-1 weight loss efficacy and side effects identified
Wednesday, April 8, 2026 – Thursday, April 9 - 23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. GLP-1 receptor agonists, including semaglutide and tirzepatide, have transformed the clinical management of weight and obesity. However, patients experience substantial variability in both weight loss efficacy and the incidence of side effects. Some individuals lose less than 5% of their body weight, whereas others lose more than 20%. Some individuals experience side effects such as nausea and vomiting, whereas others do not.